| Title: |
A Phase 1 Dose-Escalation, Food Effect, and Drug-Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR-1505, in Healthy Volunteers. |
| Authors: |
Gupta VK; Schrödinger Inc., New York, USA., Yoo B; Schrödinger Inc., New York, USA., Weiss D; Schrödinger Inc., New York, USA., Basile FG; Schrödinger Inc., New York, USA., Schuck E; Schrödinger Inc., New York, USA., Rubino CM; Institute for Clinical Pharmacodynamics, Schenectady, NY, USA., Zhang S; Schrödinger Inc., New York, USA., Maxwell SE; Schrödinger Inc., New York, USA., Zheng W; Schrödinger Inc., New York, USA., Tan JBL; Parvus Therapeutics, South San Francisco, CA, USA., Stenehjem D; University of Minnesota, College of Pharmacy, Duluth, MN, USA., Watkins PB; Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA., Dugan M; Schrödinger Inc., New York, USA., Yin W; Schrödinger Inc., New York, USA., Wright DH; Schrödinger Inc., New York, USA., Akinsanya K; Schrödinger Inc., New York, USA., Lickliter J; Nucleus Network Ltd., Melbourne, VIC, Australia. |
